GW4046, a synthetic FXR agonist, improves hepatic steatosis and insulin resistance in diet-induced obese (DIO) or ob/ob mice, though poor bioavailability limits its usage in clinical trials [141,142,143]. The gene discussed is NR1H4; the disease is Hepatic steatosis.